| Literature DB >> 25883940 |
Andrew J Mitchelson1, Craig J Wilson1, William M Mihalko2, Thomas M Grupp3, Blaine T Manning1, Douglas A Dennis4, Stuart B Goodman5, Tony H Tzeng1, Sonia Vasdev1, Khaled J Saleh1.
Abstract
The prospect of biomaterial hypersensitivity developing in response to joint implant materials was first presented more than 30 years ago. Many studies have established probable causation between first-generation metal-on-metal hip implants and hypersensitivity reactions. In a limited patient population, implant failure may ultimately be related to metal hypersensitivity. The examination of hypersensitivity reactions in current-generation metal-on-metal knee implants is comparatively limited. The purpose of this study is to summarize all available literature regarding biomaterial hypersensitivity after total knee arthroplasty, elucidate overall trends about this topic in the current literature, and provide a foundation for clinical approach considerations when biomaterial hypersensitivity is suspected.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25883940 PMCID: PMC4390183 DOI: 10.1155/2015/137287
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Hypersensitivity reactions after total joint arthroplasty reported in prospective studies.
| Prospective study title | Publication | Author | Results |
|---|---|---|---|
| Sensitivity to implant materials in patients undergoing total hip-replacement | J Biomed Mater Res |
Granchi et al. [ | Patch test unable to differentiate stable versus unstable implants, equivalent implant lifespan in metal patch +; 10 yr survival for metal patch + 44% versus patch − 47%; poor survival for cement patch + |
| Allergy to components of total hip arthroplasty before and after surgery | Ital J Orthop Traumatol | Cancilleri et al. [ | 10/66 THA patch + (1/12 w/aseptic loosening patch +), 2/41 preop. patch +; hypersensitivity may play role in loosening, but likely small |
| Metal sensitivity in patients with metal-to-plastic total hip arthroplasties | Acta Orthop Scand | Carlsson et al. [ | 9/112 patch + preop., 12/112 patch + postop.; all complications except 1/246 explained by reasons other than hypersensitivity |
| Allergy in hip arthroplasty | Contact Dermatitis | Waterman and Schrik [ | 13/85 patch + preop. (13 metal), 25/85 patch + postop. (23 metal, 2 cement), 0/10 loose THA patch +; no evidence to suggest loosening because of hypersensitivity |
| The development of metal hypersensitivity in patients with metal-to-plastic hip arthroplasties | Contact Dermatitis | Nater et al. [ | 0/66 patch + preop., 4/66 patch + MOP conversion postop.; no clinical sequelae, no need to test |
| Metal sensitivity in patients with orthopedic implants: a prospective study | Contact Dermatitis | Frigerio et al. [ | 16/72 (22%) preop. + patch or LTT, (19/72 (29%) postop. (5 conversions of 72 total)); if preop. history insufficient, recommend for screening tests |
| Metal sensitivity before and after total hip arthroplasty | J Bone Joint Surg Am | Deutman et al. [ | 10/173 patch + preop., 4/66 converted patch + postop. MOP; no conclusion |
| Metal sensitivity in patients undergoing hip-replacement | J Bone Joint Surg Br | Rooker and Wilkinson [ | 6/69 patch + preop. MOP, only 1/54 patch + postop.; patch + may be effect not cause, no need to screen in MOP |
| The effect of patch testing on surgical practices and outcomes in orthopedic patients with metal implants | Arch Dermatol | Mesinkovska et al. [ | 31 with history of hypersensitivity preop., 21 patch +, all did well with “allergen-free” implants; 41 suspected of hypersensitivity w/TJA, 10 patch +, 6/10 had resolution of symptoms with allergen free implant; recommend patch testing in those with history |
| Screening for symptomatic metal sensitivity: a prospective study of 92 patients undergoing total knee arthroplasty | Biomaterials | Niki et al. [ | 24/92 TKA were mLST+ preop., 5/24 developed eczema, Cr + in eczema patients but not in others; screening indicated |
|
| |||
| Prospective study summary | Preop. patch/LTT +: 56/618 (9.1%), postop.: 73/521 (14.1%) | ||
Hypersensitivity reactions after total joint arthroplasty in retrospective studies.
| Retrospective study title | Publication | Author | Results |
|---|---|---|---|
| Contact allergy to metals and bone cement components in patients with intolerance of arthroplasty | Dtsch Med Wochenschr | Eben et al. [ | In cemented TJA: 22/66 symptomatic pts. patch +, asymptomatic patch + 3/26 |
| Allergy to metals as a cause of orthopaedic implant failure | Int J Occup Med Environ Health |
Kręcisz et al. [ | 14 poor implants, 8 patch + (7 ni, 6 cr), 3 underwent revision and improved |
| Early osteolysis following second-generation metal-on-metal hip-replacement | J Bone Joint Surg Am | Park et al. [ | 8/9 MoM w/osteolysis patch + to Co, 2/9 w/o osteolysis patch +; retrospective |
| Sensitivity to metal as a possible cause of sterile loosening after cobalt-chromium total hip-replacement arthroplasty | J Bone Joint Surg Am | Brown et al. [ | 0/20 loose MoM patch + (1977) |
| Metal sensitivity as a cause of bone necrosis and loosening of the hip prosthesis in total joint replacement | J Bone Joint Surg Br | Evans et al. [ | 9/14 w/loose joints patch +, 0/24 w/stable joints |
| Incidence of metal sensitivity in patients with total joint replacements | Br Med J | Elves et al. [ | 15/23 failed TJA patch +, 4/27 stable patch +, 8/13 w/derm rxn were patch + |
| Dermatitis on the knee following knee replacement: a minority of cases contact allergy to chromate, cobalt, or nickel but a causal association is unproven | Contact Dermatitis | Verma et al. [ | 7 of 15 patients w/cutaneous symptoms patch + |
| Metal sensitivity in patients with metal-to-plastic total hip arthroplasties | Acta Orthop Scand | Carlsson et al. [ | 13/134 MOP patch + postop.; unsure if hypersensitivity caused by THA, but, in pts. w/Hx of allergy, proceed w/caution |
| Retrospective evaluation of patch testing before or after metal device implantation | Arch Dermatol | Reed et al. [ | 5/22 with history of hypersensitivity preop. patch +, 0/22 referred for patch test postop. were patch + |
| Lymphocyte responses in patients with total hip arthroplasty | J Orthop Res | Hallab et al. [ | More + LTT and cytokine release in THA, and esp. in loose THA |
|
| |||
| Retrospective study summary | Revised: 33/138 (23.9%) patch +, 44/303 (14.5%) patch + in stable TJA | ||
Summary of case reports of metallic knee implant associated hypersensitivity reactions.
| Number of implants | Patient gender | History of metal allergy | Implant components | Presenting signs and symptoms | Patch test result | LTT result | Initial implant outcome | Treatment | Revision implant components | |
|---|---|---|---|---|---|---|---|---|---|---|
| Beecker et al. [ | 2 (1 patient) | Female | Yes | Cobalt-chromium alloy | Erythema, edema, heat, eczema | Cobalt, nickel | Stable | Triamcinolone, diphenhydramine | ||
|
Bergschmidt et al. [ | 1 | Female | Cobalt-chromium alloy | Arthralgia, heat, decreased ROM | Nickel sulfate, palladium chloride | Stable | Revision | Ceramic, titanium | ||
| Dietrich et al. [ | 4 | Female | Yes | Cobalt-chromium-molybdenum alloy | Arthralgia, erythema, edema | Cobalt, nickel | Cobalt, nickel | Stable (3) | Revision | Titanium |
| Gao et al. [ | 1 | Male | No | Cobalt-chromium-molybdenum alloy | Eczema, systemic dermatitis, decreased ROM | Chromium | Stable | Revision | Zirconium-niobium alloy | |
| Handa et al. [ | 1 | Male | No | Copper-chromium alloy | Eczema, exudate | Cobalt, copper | Stable | |||
| Oiso et al. [ | 1 | Male | Cobalt-chromium alloy | Erythema, edema, arthralgia, fever | Cobalt, chromium, nickel, manganese | Stable | Revision | Ceramic, titanium | ||
| Thomsen et al. [ | 1 | Female | Arthralgia, eczema decreased ROM | Negative | Stable | Revision | Zirconium-nitride coating | |||
| van Opstal and Verheyden [ | 1 | Female | Yes | Titanium-aluminum-vanadium | Arthralgia, eczema, edema | Negative | Failure | Revision | Zirconium alloy | |
| Verma et al. [ | 15 | Female (13) | No | Cobalt-chromium alloy | Eczema | Nickel (4) | Stable | Topical corticosteroid |
Figure 1
Figure 2